Less than a year after Amgen ($AMGN) puzzled market watchers with a high-dollar deal for the once-bankrupt deCODE, the Icelandic company's former owners have found a ...
NextCODE Health Launches Operations with Exclusive License to Leverage deCODE genetics' Genomics Platform for Sequence-Based Clinical Diagnostics, and $15 Million in Venture Financing CAMBRIDGE, Mass.
Funding from the SBRI will go toward determining structures of protein related to emerging or re-emerging infectious diseases. deCODE biostructures received a five-year, $13.5 million collaborative ...
A decade ago, genomics-based companies were all the rage. Then one by one nearly all of the high-fliers of that era went bust, were acquired, or restructured (Celera, Orchid, etc). One of the last to ...
Over a year into its attempts to revamp its business and reduce its debt, Icelandic firm deCode genetics has filed for bankruptcy. The storied genomics company was founded in 1996 and quickly gained ...
During the last quarter of 2003, two genomics companies—deCODE genetics (Reykjavik) and Lexicon Genetics (The Woodlands, TX, USA)—announced significant progress in efforts to strengthen their product ...
After struggling financially for years, the genomics company deCODE, based in Reykjavik, Iceland, filed for bankruptcy on 16 November. The question now is whether other companies looking to ...
CAMBRIDGE, Mass., Oct. 23, 2013 /PRNewswire/ -- NextCODE Health, a new private company enabling accelerated diagnosis of genetic diseases through the use of sequence data, announced today that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback